Medigen Biotechnology Corp.
TWO: 3176.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shi-Chung Chang
- Employees
- 67
- Headquarters
- Taipei, Taiwan
- IPO year
- 2007
- Market cap
- NT$4.6B
- Website
- https://www.medigen.com.tw
Loading 3176…
Loading profile data…Frequently asked questions about 3176
What does Medigen Biotechnology Corp. (3176.TWO) do?
Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with eso...
Where does 3176.TWO trade?
Medigen Biotechnology Corp. (3176.TWO) trades on the Taipei Exchange.
What sector is 3176.TWO in?
Medigen Biotechnology Corp. (3176.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Medigen Biotechnology Corp.?
Shi-Chung Chang is the chief executive officer of Medigen Biotechnology Corp. (3176.TWO).
Where is Medigen Biotechnology Corp. headquartered?
Medigen Biotechnology Corp. is headquartered in Taiwan.
Does 3176.TWO pay a dividend?
Medigen Biotechnology Corp. (3176.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 3176.TWO go public?
Medigen Biotechnology Corp. (3176.TWO) completed its initial public offering in 2007.